ES2525931T3 - Composiciones y métodos para prevenir o tratar enfermedad inflamatoria intestinal - Google Patents

Composiciones y métodos para prevenir o tratar enfermedad inflamatoria intestinal Download PDF

Info

Publication number
ES2525931T3
ES2525931T3 ES06840359.1T ES06840359T ES2525931T3 ES 2525931 T3 ES2525931 T3 ES 2525931T3 ES 06840359 T ES06840359 T ES 06840359T ES 2525931 T3 ES2525931 T3 ES 2525931T3
Authority
ES
Spain
Prior art keywords
inflammatory bowel
bowel disease
compositions
methods
prevent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES06840359.1T
Other languages
English (en)
Inventor
Christina Khoo
William D. Schoenherr
Kathy L. Gross
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hills Pet Nutrition Inc
Original Assignee
Hills Pet Nutrition Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hills Pet Nutrition Inc filed Critical Hills Pet Nutrition Inc
Application granted granted Critical
Publication of ES2525931T3 publication Critical patent/ES2525931T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physiology (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Fodder In General (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Feed For Specific Animals (AREA)

Abstract

Ácido docosahexaenoico para uso en la prevención o tratamiento de enfermedad inflamatoria del intestino en un felino susceptible de o que sufre de enfermedad inflamatoria del intestino, prevención o tratamiento que comprende administrar desde aproximadamente 6 hasta aproximadamente 165 mg/kg de peso corporal/día de ácido docosahexaenoico al felino.

Description

imagen1
imagen2
imagen3

Claims (1)

  1. imagen1
    imagen2
ES06840359.1T 2005-12-29 2006-12-29 Composiciones y métodos para prevenir o tratar enfermedad inflamatoria intestinal Active ES2525931T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US75480605P 2005-12-29 2005-12-29
US754806P 2005-12-29
PCT/US2006/062699 WO2007076531A1 (en) 2005-12-29 2006-12-29 Compositions and methods for preventing or treating inflammatory bowel disease

Publications (1)

Publication Number Publication Date
ES2525931T3 true ES2525931T3 (es) 2015-01-02

Family

ID=37888012

Family Applications (1)

Application Number Title Priority Date Filing Date
ES06840359.1T Active ES2525931T3 (es) 2005-12-29 2006-12-29 Composiciones y métodos para prevenir o tratar enfermedad inflamatoria intestinal

Country Status (12)

Country Link
US (5) US8048922B2 (es)
EP (1) EP1976501B1 (es)
JP (1) JP2009525949A (es)
CN (2) CN103933021B (es)
AU (1) AU2006330418B2 (es)
BR (1) BRPI0620719A2 (es)
CA (3) CA2633686C (es)
DK (1) DK1976501T3 (es)
ES (1) ES2525931T3 (es)
RU (1) RU2397760C2 (es)
WO (1) WO2007076531A1 (es)
ZA (1) ZA200805419B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1976501T3 (en) * 2005-12-29 2014-11-24 Hills Pet Nutrition Inc Compositions and methods for the prevention or treatment of inflammatory bowel disease
US20080161275A1 (en) * 2006-12-05 2008-07-03 Resolvyx Pharmaceuticals, Inc. Compositions and methods for the treatment of inflammatory disease
WO2009142713A1 (en) * 2008-05-19 2009-11-26 Nestec S.A. Methods for reducing lipid absorption by an animal
AU2009309237B2 (en) 2008-10-31 2016-02-25 Lipid Pharmaceuticals Ehf. Fatty acids for use as a medicament
CA2797539C (en) * 2010-05-12 2016-07-05 Hill's Pet Nutrition, Inc. Methods of diagnosis, control and prophylaxis of inflammation and mitigation of inflammatory conditions in felines
KR102399290B1 (ko) * 2014-05-08 2022-05-17 디에스엠 아이피 어셋츠 비.브이. 10-하이드록시-2-데센산을 포함하는 방법 및 조성물
US10973244B2 (en) 2017-11-17 2021-04-13 Hills Pet Nutrition, Inc. Compositions comprising omega-3 polyunsaturated and medium chain fatty acids
CN111329997A (zh) * 2020-03-04 2020-06-26 山东信得科技股份有限公司 一种治疗猫炎症性肠道疾病的软咀嚼片剂及其制备方法
AU2021253003B2 (en) * 2020-04-06 2024-02-15 Hill's Pet Nutrition, Inc. Pet food compositions

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5484611A (en) * 1992-07-15 1996-01-16 The Scottish Agricultural College Method of producing a fatty acid
DE60127829T2 (de) * 2000-05-01 2007-12-27 The Iams Company, Dayton Haustierfutterzusammensetzung zur verminderung der entzündungsreaktion in katzen
CA2420266A1 (en) * 2003-02-28 2004-08-28 Wayne Mackinnon Oral omega-3 fatty acid neutritional supplement for companion animals
WO2004095940A1 (en) * 2003-04-25 2004-11-11 The University Of Newcastle Biomass containing animal feed
GB0314624D0 (en) * 2003-06-23 2003-07-30 Advanced Bionutrition Europ Lt Inflammatory disease treatment
SE0303513D0 (sv) * 2003-12-19 2003-12-19 Pronova Biocare As Use of a fatty acid composition comprising at least one of epa and dha or any combinations thereof
CN101150962A (zh) * 2004-12-30 2008-03-26 希尔氏宠物营养品公司 提高幼年动物生活质量的方法
DK1976501T3 (en) * 2005-12-29 2014-11-24 Hills Pet Nutrition Inc Compositions and methods for the prevention or treatment of inflammatory bowel disease

Also Published As

Publication number Publication date
CN103933021B (zh) 2017-04-12
US8048922B2 (en) 2011-11-01
CA2633686A1 (en) 2007-07-05
CA2845158C (en) 2016-07-05
DK1976501T3 (en) 2014-11-24
BRPI0620719A2 (pt) 2012-09-18
CA2845158A1 (en) 2007-07-05
US20070185201A1 (en) 2007-08-09
CA2845041A1 (en) 2007-07-05
EP1976501B1 (en) 2014-10-22
US8153691B2 (en) 2012-04-10
AU2006330418A1 (en) 2007-07-05
WO2007076531A1 (en) 2007-07-05
US20120142009A1 (en) 2012-06-07
RU2397760C2 (ru) 2010-08-27
CA2633686C (en) 2014-05-13
ZA200805419B (en) 2014-08-27
US9408817B2 (en) 2016-08-09
RU2008131069A (ru) 2010-02-10
AU2006330418B2 (en) 2010-07-15
US20090263855A1 (en) 2009-10-22
US20170135974A1 (en) 2017-05-18
JP2009525949A (ja) 2009-07-16
CN101370490A (zh) 2009-02-18
US20090253791A1 (en) 2009-10-08
CN103933021A (zh) 2014-07-23
EP1976501A1 (en) 2008-10-08

Similar Documents

Publication Publication Date Title
ES2525931T3 (es) Composiciones y métodos para prevenir o tratar enfermedad inflamatoria intestinal
ES2611483T3 (es) Agente terapéutico para enfermedad inflamatoria intestinal
CO6331425A2 (es) Composiciones que comprenden n-(3,4-difluoro-2-(2-fluoro-4-yodofenilamino)6-metoxifenil)-1-(2,3-dihidroxiproxipropil)ciclopropan-1-sulfamida
MX2007000304A (es) Metodo de tratamiento de enfermedad de almacenamiento de glucogeno o polisacaridos.
ES2581331T3 (es) Inhibidor de la progresión de una enfermedad atribuida a una acumulación anormal de grasa hepática
MXPA05009595A (es) Compuestos 7-amino-isoindolilo y sus usos farmaceuticos.
GT200600163A (es) Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de la depresion
BRPI0513843A (pt) composto ou um sal ou solvato ou uma pró-droga farmaceuticamente aceitável do mesmo, composição farmacêutica, forma de dosagem, uso de um composto, e, sal de cloridrato
BRPI0618239A8 (pt) uso de flibanserina para o tratamento de distúrbios de desejo sexual pré-menopáusicos
BRPI0416628A (pt) uso de compostos orgánicos
AR075735A1 (es) Composiciones farmaceuticas de liberacion inmediata que comprenden oxicodona y naloxona. uso
TW200735874A (en) Use of PDE III inhibitors for the treatment of asymptomatic (occult) heart failure
AR058163A1 (es) Medicamentos exhaltadores del deseo sexual que comprenden derivados de benzimidazolona
AR062397A1 (es) Uso de compuestos y derivados de 2,5-dihidroxibenceno para el tratamiento de fibrosis
ES2552654T3 (es) Uso de LCAT para tratar la anemia y la disfunción de los glóbulos rojos
MY147391A (en) Treatment of chronic kidney disease (ckd) subjects using lanthanum compounds
AR062659A1 (es) Composicion de liberacion sostenida de levodopa y metodo para su uso
CL2007001748A1 (es) Compuesto derivado de 2-arilamino-4-aminopirimidinas, inhibidores de la proteina quinasa c-alfa; composiciones farmaceuticas que los contienen; y su uso para tratar o prevenir la diabetes, el cancer, enfermedades cardiovasculares y otras.
GT200600263A (es) Regimen de dosificacion para prasugrel
AR064543A1 (es) Uso de derivados de mononitrato de dianhidrohexita como agentes para el tratamiento de trastornos intestinales
CL2007000485A1 (es) Sal de alisquereno; procedimiento de preparacion; composicion farmaceutica que comprende a dicha sal; y uso del compuesto para el tratamiento de enfermedades que puedan ser moduladas mediante la inhibicion de la renina.
CL2004000535A1 (es) Composicion farmaceutica que comprende rapamicina o un derivado de rapamicina y pimecrolimus; y su uso para el tratamiento de enfermedad inflamatoria del intestino.
AR052015A1 (es) Agente para la profilaxis o tratamiento del sindrome metabolico
ES2533046T3 (es) Oleíl-fosfocolina
PA8789101A1 (es) Composición farmacéutica estable que comprende una sal de vinflunina hidrosoluble